stonks4u
Sign up free
MGTX logo

MGTX MeiraGTx Holdings plc

NASDAQ Global Select · Biotechnology · Healthcare

$13.52
+0.85 (+6.71%)

MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The comp…

Market Cap: $1.25Bwww.meiragtx.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
607387100
Aug 11Aug 13

Quote

Day Range
$12.44 – $13.77
52-Week Range
$6.62 – $15.35
Volume
$795.4K
Market Cap
$1.25B
50-Day Avg
$11.96
200-Day Avg
$9.30
Prev Close
$12.67
Open
$12.46

Valuation & Ratios

P/E Ratio
-5.60
EPS
$-1.42
P/B Ratio
-110.38
P/S Ratio
7.86
Debt/Equity
-15.31
Current Ratio
0.75
Dividend Yield
+0.0%
Gross Margin
+94.0%

Returns & Efficiency

Return on Equity
+1971.4%
Return on Assets
-46.7%
FCF Yield
-7.8%
EV/EBITDA
-7.41

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$81.39M$-114.20M$-1.42
2024$33.28M$-147.79M$-2.12
2023$14.02M$-84.03M$-1.49
2022$15.92M$-129.62M$-2.87
2021$37.70M$-79.56M$-1.80

Social Signal Score

31
5d
31
2 mentions
—
30d
31
2 mentions
—
60d
31
2 mentions
—
90d
31
2 mentions
—
news: 2

Earnings

Thu, Nov 12(in 3 months)

Consensus estimate $-0.50 per share

3of 7 quarters beat consensus

Typical surprise -4.2% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 13$1.71 vs $-0.46beat
  • Thu, May 14$-0.57 vs $-0.43miss
  • Thu, Mar 26$0.19 vs $-0.60beat
  • Thu, Nov 13$-0.62 vs $-0.50miss
  • Thu, Aug 14$-0.48 vs $-0.52beat
  • Tue, May 13$-0.51 vs $-0.38miss

Estimates and results for MGTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

MGTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (2)

  • Newszacks.com·2d ago·Neutral

    MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates MeiraGTx Holdings PLC (MGTX) came out with quarterly earnings of $1.71 per share, beating the Zacks Consensus Estimate of a loss of $0.39 per share. This compares to a loss of $0.48 per share a year ago.

    View source ↗
  • Newsprnewswire.com·4d ago·Negative

    Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia Graviton received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a novel capsule formulation of GV101 on August 7, 2026. FDA clearance marks a critical regulatory milestone in advancing this formulation of GV101, a capsule with improved PK and oral availability, into human trials for Friedreich's ataxia (FA).

    View source ↗